Deficiency for the Cysteine Protease Cathepsin L Promotes Tumor

Total Page:16

File Type:pdf, Size:1020Kb

Deficiency for the Cysteine Protease Cathepsin L Promotes Tumor Oncogene (2010) 29, 1611–1621 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 $32.00 www.nature.com/onc ORIGINAL ARTICLE Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis J Dennema¨rker1,6, T Lohmu¨ller1,6, J Mayerle2, M Tacke1, MM Lerch2, LM Coussens3,4, C Peters1,5 and T Reinheckel1,5 1Institute for Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany; 2Department of Gastroenterology, Endocrinology and Nutrition, Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany; 3Department of Pathology, University of California, San Francisco, CA, USA; 4Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA and 5Ludwig Heilmeyer Comprehensive Cancer Center and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany To define a functional role for the endosomal/lysosomal Introduction cysteine protease cathepsin L (Ctsl) during squamous carcinogenesis, we generated mice harboring a constitutive Proteases have traditionally been thought to promote Ctsl deficiency in addition to epithelial expression of the invasive growth of carcinomas, contributing to the the human papillomavirus type 16 oncogenes (human spread and homing of metastasizing cancer cells (Dano cytokeratin 14 (K14)–HPV16). We found enhanced tumor et al., 1999). Proteases that function outside tumor cells progression and metastasis in the absence of Ctsl. As have been implicated in these processes because of their tumor progression in K14–HPV16 mice is dependent well-established release from tumors, causing the break- on inflammation and angiogenesis, we examined immune down of basement membranes and extracellular matrix. cell infiltration and vascularization without finding any Thus, extracellular proteases may in part facilitate effect of the Ctsl genotype. In contrast, keratinocyte- tumor cell invasion into ectopic tissue by the generation specific transgenic expression of cathepsin V, the human of bioactive factors from extracellular matrix macro- orthologue of mouse Ctsl, in otherwise Ctsl-deficient K14– molecules (Kalluri, 2003; DeClerck et al., 2004). The HPV16 mice restored the phenotype observed in the groups of tumor-promoting proteolytic enzymes consist control HPV16 skin. To better understand this phenotype of: soluble and integral membrane matrix metallopro- at the molecular level, we measured several oncogenic teases (MMP, MT-MMP, and ADAMTS), serine signal transduction pathways in primary keratinocytes on proteases and inhibitors of the plasminogen activator/ stimulation with keratinocyte-conditioned cell culture plasminogen system, and cysteine- and aspartyl-type medium. We found increased activation of protein kinase endosomal/lysosomal peptidases (Liotta and Kohn, B/Akt and mitogen-activated protein kinase pathways in 2001; Mohamed and Sloane, 2006). Alternatively, a protease-deficient cells, especially if treated with media number of proteases are considered to have tumor- conditioned by Ctsl-deficient keratinocytes. Similarly, the suppressive functions (Lopez-Otin and Matrisian, 2007). level of active GTP-Ras was increased in Ctsl-deficient This paradox is easily appreciated for caspases that epidermis. We conclude that Ctsl is critical for the regulate cell death programming in cells through termination of growth factor signaling in the endosomal/ initiation and execution of apoptotic programs. How- lysosomal compartment of keratinocytes and, therefore, ever, there is also evidence of anti-tumor functions for functions as an anti-tumor protease. some members of the extracellular metalloprotease Oncogene (2010) 29, 1611–1621; doi:10.1038/onc.2009.466; families, including MMPs and ADAMTS (Martin and published online 21 December 2009 Matrisian, 2007). The major mechanism(s) underlying anti-tumor functions is thought to result from the Keywords: skin cancer; mouse model; protease; inhibition of tumor angiogenesis because of the genera- cathepsin tion of anti-angiogenic peptides (Nyberg et al., 2008). Cathepsin L (Ctsl) is an endosomal/lysosomal papain- like cysteine endoprotease implicated in a variety of physiological and pathological processes (Vasiljeva et al., 2007). The mouse genome encodes for only one Correspondence: Dr T Reinheckel, Institut fu¨r Molekulare Medizin Ctsl while in humans there is not only the ‘classical’ und Zellforschung, Albert-Ludwigs-University, Stefan Meier Strasse cathepsin L (CTSL) but also the related cysteine 17, Freiburg, D-79104, Germany. protease cathepsin V (CTSV), which is frequently E-mail: [email protected] 6These authors contributed equally to this work. termed cathepsin L2. Human CTSV and murine Ctsl Received 1 July 2009; revised 7 October 2009; accepted 16 November are true orthologues because they share 75% amino 2009; published online 21 December 2009 acid sequence identity, whereas the homology of murine Cathepsin L in skin cancer J Dennema¨rker et al 1612 Ctsl and human CTSL is less pronounced (Bro¨mme, Results 2004). However, human CTSL is ubiquitously ex- pressed, whereas CTSV expression is restricted to Ctsl deficiency potentiates neoplastic progression macrophages, thymus, testis, corneal epithelium and— in K14–HPV16 transgenic mice importantly—the epidermis (Bernard et al., 2003; Cysteine cathepsins, such as Ctsl, are considered to be Tolosa et al., 2003; Cheng et al., 2006). In a variety of multifunctional proteases in cancer (Mohamed human cancers expression levels of CTSL have been and Sloane, 2006). To evaluate which aspects of positively correlated with poor prognosis (Jedeszko and neoplastic progression Ctsl might regulate, we back- Sloane, 2004), while CTSV is transcriptionally upregu- crossed CtslÀ/À mice (Roth et al., 2000) into the FVB/n lated in skin squamous cell carcinomas (SCCs) as genetic background and crossed them to congenic compared with the benign hyperproliferation in psor- K14–HPV16 (HPV16) mice. We found that HPV16/ iatic skin (Haider et al., 2006). In addition to their CtslÀ/À mice developed the first palpable tumors intracellular localization, the various human and murine significantly earlier than HPV16/Ctsl þ /À and HPV16/ Ctsl enzymes have been detected in the extracellular Ctsl þ / þ littermates (Figure 1a). The final tumor size of portion of the plasma membrane and secreted into the 1cm3 appeared in the HPV16/CtslÀ/À mice approxi- extracellular space. Ctsl released by carcinoma cells has mately 10 weeks earlier than in the controls (Figure 1b). been shown to produce the angiogenesis inhibitor In addition, histopathological grading of carcinomas endostatin from collagen XVIII, the core protein of from HPV16/CtslÀ/À mice revealed the emergence of heparan sulfate proteoglycans in vascular and epithelial only poorly differentiated grade III and grade IV SCCs basement membranes (Felbor et al., 2000). In contrast, as opposed to a higher percentage of well- and Urbich et al. showed that Ctsl is actually critical for the moderately differentiated SCCs in littermate controls invasive capacity of endothelial progenitor cells, pro- (Figure 1c). To further assess the histological character- moting neovascularization (Urbich et al., 2005). Intra- istics of carcinomas, we quantified membrane-bound cellular Ctsl has been identified as a positive regulator of E-cadherin in grade III SCCs from HPV16/Ctsl þ / þ and insulin-like growth factor 1 receptor signaling and of the HPV16/CtslÀ/À mice (Figure 1d). We found that experimental metastasis of tumor cells, which are membrane-bound E-cadherin was reduced in the dependent on insulin-like growth factor 1 receptor, Ctsl-deficient carcinomas, substantiating their poor and has also been found to have a role in promoting histological differentiation and suggesting a highly resistance toward chemotherapeutic drugs (Zheng et al., invasive and potentially metastatic phenotype. Accord- 2004; Navab et al., 2008). N-terminally truncated Ctsl ingly, the frequency of metastases in axillary lymph has been found in the nucleus, in which it activates the nodes was found to be significantly higher in the Ctsl- CDP/Cux transcription factor, a positive regulator of deficient mice, 25% in the HPV16/Ctsl þ / þ cohort and the cell cycle involved in cellular transformation (Goulet 70% in HPV16/CtslÀ/À mice (Figure 1e). The early onset et al., 2007). and poor state of differentiation in HPV16/CtslÀ/À As of the multiple potential mechanisms by which cancers was preceded by an earlier development Ctsl might affect tumor progression, we decided of dysplasias (Figure 2a). Epidermal dysplasia was to analyze this protease in a complex in vivo model found at 16 weeks of age in each of the HPV16/CtslÀ/À of tumorigenesis that mimics the successive stages mice, whereas only 50% of control mice had advanced of human cancer development. Therefore, we used to the dysplastic state by this time point. Quantification K14–HPV16 transgenic mice as a mouse model of of the cell proliferation marker Ki67 revealed signifi- epidermal carcinogenesis (Arbeit et al., 1994; Coussens cantly increased percentages of proliferating keratino- et al., 1996). K14–HPV16 mice express the early cytes in the premalignant epidermis of HPV16/CtslÀ/À region genes of human papillomavirus type 16 mice at 8, 16 and 24 weeks of age (Figures 2b and c). (HPV16) under the control of the human cytokeratin Together, these data indicate a potential anti-tumor role 14 (K14) promoter. HPV16 transgenic mice show a for Ctsl
Recommended publications
  • Supplementary Data
    Supplementary Data for Quantitative Changes in the Mitochondrial Proteome from Subjects with Mild Cognitive Impairment, Early Stage and Late Stage Alzheimer’s disease Table 1 - 112 unique, non-redundant proteins identified and quantified in at least two of the three analytical replicates for all three disease stages. Table 2 - MCI mitochondrial samples, Protein Summary Table 3 - MCI mitochondrial samples, Experiment 1 Table 4 - MCI mitochondrial samples, Experiment 2 Table 5 - MCI mitochondrial samples, Experiment 3 Table 6 - EAD Mitochondrial Study, Protein Summary Table 7 - EAD Mitochondrial Study, Experiment 1 Table 8 - EAD Mitochondrial Study, Experiment 2 Table 9 - EAD Mitochondrial Study, Experiment 3 Table 10 - LAD Mitochondrial Study, Protein Summary Table 11 - LAD Mitochondrial Study, Experiment 1 Table 12 - LAD Mitochondrial Study, Experiment 2 Table 13 - LAD Mitochondrial Study, Experiment 3 Supplemental Table 1. 112 unique, non-redundant proteins identified and quantified in at least two of the three analytical replicates for all three disease stages. Description Data MCI EAD LAD AATM_HUMAN (P00505) Aspartate aminotransferase, mitochondrial precursor (EC Mean 1.43 1.70 1.31 2.6.1.1) (Transaminase A) (Glutamate oxaloacetate transaminase 2) [MASS=47475] SEM 0.07 0.09 0.09 Count 3.00 3.00 3.00 ACON_HUMAN (Q99798) Aconitate hydratase, mitochondrial precursor (EC 4.2.1.3) Mean 1.24 1.61 1.19 (Citrate hydro-lyase) (Aconitase) [MASS=85425] SEM 0.05 0.17 0.18 Count 3.00 2.00 3.00 ACPM_HUMAN (O14561) Acyl carrier protein, mitochondrial
    [Show full text]
  • Data Sheet Cathepsin V Inhibitor Screening Assay Kit Catalog #79589 Size: 96 Reactions
    6405 Mira Mesa Blvd Ste. 100 San Diego, CA 92121 Tel: 1.858.202.1401 Fax: 1.858.481.8694 Email: [email protected] Data Sheet Cathepsin V Inhibitor Screening Assay Kit Catalog #79589 Size: 96 reactions BACKGROUND: Cathepsin V, also called Cathepsin L2, is a lysosomal cysteine endopeptidase with high sequence homology to cathepsin L and other members of the papain superfamily of cysteine proteinases. Its expression is regulated in a tissue-specific manner and is high in thymus, testis and cornea. Expression analysis of cathepsin V in human tumors revealed widespread expression in colorectal and breast carcinomas, suggesting a possible role in tumor processes. DESCRIPTION: The Cathepsin V Inhibitor Screening Assay Kit is designed to measure the protease activity of Cathepsin V for screening and profiling applications. The Cathepsin V assay kit comes in a convenient 96-well format, with purified Cathepsin V, its fluorogenic substrate, and Cathepsin buffer for 100 enzyme reactions. In addition, the kit includes the cathepsin inhibitor E- 64 for use as a control inhibitor. COMPONENTS: Catalog # Component Amount Storage 80009 Cathepsin V 10 µg -80 °C Fluorogenic Cathepsin Avoid 80349 Substrate 1 (5 mM) 10 µl -20 °C multiple *4X Cathepsin buffer 2 ml -20 °C freeze/thaw E-64 (1 mM) 10 µl -20 °C cycles! 96-well black microplate * Add 120 µl of 0.5 M DTT before use. MATERIALS OR INSTRUMENTS REQUIRED BUT NOT SUPPLIED: 0.5 M DTT in aqueous solution Adjustable micropipettor and sterile tips Fluorescent microplate reader APPLICATIONS: Great for studying enzyme kinetics and screening small molecular inhibitors for drug discovery and HTS applications.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Sdouglas Cathepsin
    CATHEPSIN-MEDIATED FIBRIN(OGEN)OLYSIS IN ENGINEERED MICROVASCULAR NETWORKS AND CHRONIC COAGULATION IN SICKLE CELL DISEASE A Dissertation Presented to The Academic Faculty by Simone Andrea Douglas In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the School of Wallace H. Coulter Department of Biomedical Engineering Georgia Institute of Technology and Emory University August 2020 COPYRIGHT © 2020 BY SIMONE A. DOUGLAS CATHEPSIN-MEDIATED FIBRIN(OGEN)OLYSIS IN ENGINEERED MICROVASCULAR NETWORKS AND CHRONIC COAGULATION IN SICKLE CELL DISEASE Approved by: Dr. Manu O. Platt, Advisor Dr. Clint Joiner Department of Biomedical Engineering Department of Pediatrics, Division of Georgia Institute of Technology Hematology/Oncology Emory University School of Medicine Dr. Rodney Averett Dr. Roger Kamm School of Mechanical Engineering Department of Mechanical Engineering University of Georgia & Department of Biological Engineering Massachusetts Institute of Technology Dr. Edward Botchwey Dr. Johnna Temenoff Department of Biomedical Engineering Department of Biomedical Engineering Georgia Institute of Technology Georgia Institute of Technology Date Approved: April 24, 2020 For Mom and Dad And to the people of Jamaica “Out of Many, One People” One Love. ACKNOWLEDGEMENTS I would like to start by acknowledging my PhD Advisor, Dr. Manu Platt. I owe a lot of my growth as a person and scientist over the past five years to him. Dr. Platt has challenged me, pushing me out of my comfort zone and encouraging me to grow far beyond what I thought I was capable of. Through Dr. Platt’s encouragement I was lucky to have many opportunities and experiences in graduate school- international travel, earning travel and poster presentation awards, mentoring Project ENGAGES scholars and REU students, serving as a lead volunteer for BME graduate recruitment, mentoring ESTEEMED scholars in the summer bridge program, and attending events to support the Sickle Cell Foundation of Georgia.
    [Show full text]
  • Felipe Jun Fuzita Molecular Physiology of Digestion In
    FELIPE JUN FUZITA MOLECULAR PHYSIOLOGY OF DIGESTION IN ARACHNIDA: FUNCTIONAL AND COMPARATIVE-EVOLUTIONARY APPROACHES Thesis presented to the Programa de Pós-Graduação Interunidades em Biotecnologia USP/Instituto Butantan/IPT, to obtain the Title of Doctor in Biotechnology. São Paulo 2014 FELIPE JUN FUZITA MOLECULAR PHYSIOLOGY OF DIGESTION IN ARACHNIDA: FUNCTIONAL AND COMPARATIVE-EVOLUTIONARY APPROACHES Thesis presented to the Programa de Pós-Graduação Interunidades em Biotecnologia USP/Instituto Butantan/IPT, to obtain the Title of Doctor in Biotechnology. Concentration area: Biotechnology Advisor: Dr. Adriana Rios Lopes Rocha Corrected version. The original electronic version is available either in the library of the Institute of Biomedical Sciences and in the Digital Library of Theses and Dissertations of the University of Sao Paulo (BDTD). São Paulo 2014 DADOS DE CATALOGAÇÃO NA PUBLICAÇÃO (CIP) Serviço de Biblioteca e Informação Biomédica do Instituto de Ciências Biomédicas da Universidade de São Paulo © reprodução total Fuzita, Felipe Jun. Molecular physiology of digestion in Arachnida: functional and comparative-evolutionary approaches / Felipe Jun Fuzita. -- São Paulo, 2014. Orientador: Profa. Dra. Adriana Rios Lopes Rocha. Tese (Doutorado) – Universidade de São Paulo. Instituto de Ciências Biomédicas. Programa de Pós-Graduação Interunidades em Biotecnologia USP/IPT/Instituto Butantan. Área de concentração: Biotecnologia. Linha de pesquisa: Bioquímica, biologia molecular, espectrometria de massa. Versão do título para o português: Fisiologia molecular da digestão em Arachnida: abordagens funcional e comparativo-evolutiva. 1. Digestão 2. Aranha 3. Escorpião 4. Enzimologia 5. Proteoma 6. Transcriptoma I. Rocha, Profa. Dra. Adriana Rios Lopes I. Universidade de São Paulo. Instituto de Ciências Biomédicas. Programa de Pós-Graduação Interunidades em Biotecnologia USP/IPT/Instituto Butantan III.
    [Show full text]
  • Crystal Structure of Cathepsin X: a Flip–Flop of the Ring of His23
    st8308.qxd 03/22/2000 11:36 Page 305 Research Article 305 Crystal structure of cathepsin X: a flip–flop of the ring of His23 allows carboxy-monopeptidase and carboxy-dipeptidase activity of the protease Gregor Guncar1, Ivica Klemencic1, Boris Turk1, Vito Turk1, Adriana Karaoglanovic-Carmona2, Luiz Juliano2 and Dušan Turk1* Background: Cathepsin X is a widespread, abundantly expressed papain-like Addresses: 1Department of Biochemistry and v mammalian lysosomal cysteine protease. It exhibits carboxy-monopeptidase as Molecular Biology, Jozef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia and 2Departamento de well as carboxy-dipeptidase activity and shares a similar activity profile with Biofisica, Escola Paulista de Medicina, Rua Tres de cathepsin B. The latter has been implicated in normal physiological events as Maio 100, 04044-020 Sao Paulo, Brazil. well as in various pathological states such as rheumatoid arthritis, Alzheimer’s disease and cancer progression. Thus the question is raised as to which of the *Corresponding author. E-mail: [email protected] two enzyme activities has actually been monitored. Key words: Alzheimer’s disease, carboxypeptidase, Results: The crystal structure of human cathepsin X has been determined at cathepsin B, cathepsin X, papain-like cysteine 2.67 Å resolution. The structure shares the common features of a papain-like protease enzyme fold, but with a unique active site. The most pronounced feature of the Received: 1 November 1999 cathepsin X structure is the mini-loop that includes a short three-residue Revisions requested: 8 December 1999 insertion protruding into the active site of the protease. The residue Tyr27 on Revisions received: 6 January 2000 one side of the loop forms the surface of the S1 substrate-binding site, and Accepted: 7 January 2000 His23 on the other side modulates both carboxy-monopeptidase as well as Published: 29 February 2000 carboxy-dipeptidase activity of the enzyme by binding the C-terminal carboxyl group of a substrate in two different sidechain conformations.
    [Show full text]
  • Food Proteins Are a Potential Resource for Mining
    Hypothesis Article: Food Proteins are a Potential Resource for Mining Cathepsin L Inhibitory Drugs to Combat SARS-CoV-2 Ashkan Madadlou1 1Wageningen Universiteit en Research July 20, 2020 Abstract The entry of SARS-CoV-2 into host cells proceeds by a two-step proteolysis process, which involves the lysosomal peptidase cathepsin L. Inhibition of cathepsin L is therefore considered an effective method to prevent the virus internalization. Analysis from the perspective of structure-functionality elucidates that cathepsin L inhibitory proteins/peptides found in food share specific features: multiple disulfide crosslinks (buried in protein core), lack or low contents of a-helix structures (small helices), and high surface hydrophobicity. Lactoferrin can inhibit cathepsin L, but not cathepsins B and H. This selective inhibition might be useful in fine targeting of cathepsin L. Molecular docking indicated that only the carboxyl-terminal lobe of lactoferrin interacts with cathepsin L and that the active site cleft of cathepsin L is heavily superposed by lactoferrin. Food protein-derived peptides might also show cathepsin L inhibitory activity. Abstract The entry of SARS-CoV-2 into host cells proceeds by a two-step proteolysis process, which involves the lyso- somal peptidase cathepsin L. Inhibition of cathepsin L is therefore considered an effective method to prevent the virus internalization. Analysis from the perspective of structure-functionality elucidates that cathepsin L inhibitory proteins/peptides found in food share specific features: multiple disulfide crosslinks (buried in protein core), lack or low contents of a-helix structures (small helices), and high surface hydrophobicity. Lactoferrin can inhibit cathepsin L, but not cathepsins B and H.
    [Show full text]
  • United States Patent (10) Patent N0.: US 7,056,947 B2 Powers Et A]
    US007056947B2 (12) United States Patent (10) Patent N0.: US 7,056,947 B2 Powers et a]. (45) Date of Patent: Jun. 6, 2006 (54) AZA-PEPTIDE EPOXIDES 5,998,470 A * 12/1999 Halbert e161. ............ .. 514/482 6,331,542 B1 * 12/2001 Carr et a1. ............. .. 514/2378 (75) Inventors: James C. Powers, Atlanta, GA (US); 6,376,468 B1 4/2002 Overkleeft et a1. Juliana L. Asgian, Fullerton, CA (US); 6,387,908 B1 5/2002 Nomura et a1. Karen E. James, Cumming, GA (US); 6,462,078 B1 * 10/2002 Ono et a1. ................ .. 514/475 Zhao-Zhao Li, Norcross, GA (US) 6,479,676 B1 11/2002 Wolf 6,586,466 Bl* 7/2003 Yamashita ................ .. 5l4/483 (73) Assigneei Georgia Tech Research C0rp-, Atlanta, 6,689,765 B1 * 2/2004 Baroudy et a1. ............ .. 514/63 GA (Us) 6,831,099 B1* 12/2004 Crews e161. ............. .. 514/475 ( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 OTHER PUBLICATIONS USC‘ 1540’) by 309 days‘ Kidwai et al, CA 125; 33462, 1996* (21) Appl. No.: 10/603,054 * Cited by examiner (22) Filed; Jun- 24, 2003 Primary ExamineriDeborah C. Lambkin _ _ _ (74) Attorney, Agent, or F irmiThomas, Kayden, (65) Pnor Pubhcatlon Data Horstemeyer & Risley LLP; Todd Deveau US 2004/0048327 A1 Mar. 11, 2004 (57) ABSTRACT Related US. Application Data (60) Provisional application No. 60/394,221, ?led on Jul. _ _ _ _ _ _ _ _ _ 5’ 2002’ provisional application NO_ 60/394,023’ ?led The present 1nvent1on prov1des compos1t1ons for 1nh1b1t1ng on ]u1_ 5’ 2002, provisional application NO 60/394, proteases, methods for synthesizing the compositions, and 024, ?led on Jul, 5, 2002, methods of using the disclosed protease inhibitors.
    [Show full text]
  • Human Cathepsin V / Cathepsin L2 / Preproprotein Protein (His Tag)
    Human Cathepsin V / Cathepsin L2 / Preproprotein Protein (His Tag) Catalog Number: 10093-H08H General Information SDS-PAGE: Gene Name Synonym: CATL2; CTSL2; CTSU; CTSV; MGC125957 Protein Construction: A DNA sequence encoding the full length of human cathepsin L2 (NP_001324.2) (Met 1-Val 334) was expressed, with a C-terminal polyhistidine tag. Source: Human Expression Host: HEK293 Cells QC Testing Purity: > 95 % as determined by SDS-PAGE Bio Activity: Protein Description Measured by its ability to cleave the fluorogenic peptide substrate Z-LR- Cathepsin V (CTSV), also known as Cathepsin L2, CTSL2, and CATL2, is AMC, (R&D Systems, Catalog # ES008) . The specific activity is >1000 a member of the peptidase C1 family. It is predominantly expressed in the pmoles/min/μg. thymus and testis. Cathepsin V is also expressed in corneal epithelium, and to a lesser extent in conjuctival epithelium and skin. It is a lysosomal Endotoxin: cysteine proteinase that may play an important role in corneal physiology. It has about 75% protein sequence identity to murine cathepsin L. The fold < 1.0 EU per μg of the protein as determined by the LAL method of this enzyme is similar to the fold adopted by other members of the papain superfamily of cysteine proteases. Cathepsin V has been recently Stability: described as highly homologous to Cathepsin L and exclusively expressed Samples are stable for up to twelve months from date of receipt at -70 ℃ in human thymus and testis. Cathepsin V is the dominant cysteine protease in cortical human thymic epithelial cells, while Cathepsin L and Predicted N terminal: Val 18 Cathepsin S seem to be restricted to dendritic and macrophage-like cells.
    [Show full text]
  • Cysteine Cathepsins: from Structure, Function and Regulation to New Frontiers☆
    Biochimica et Biophysica Acta 1824 (2012) 68–88 Contents lists available at SciVerse ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbapap Review Cysteine cathepsins: From structure, function and regulation to new frontiers☆ Vito Turk a,b,⁎⁎, Veronika Stoka a, Olga Vasiljeva a, Miha Renko a, Tao Sun a,1, Boris Turk a,b,c,Dušan Turk a,b,⁎ a Department of Biochemistry and Molecular and Structural Biology, J. Stefan Institute, Jamova 39, SI-1000 Ljubljana, Slovenia b Center of Excellence CIPKEBIP, Ljubljana, Slovenia c Center of Excellence NIN, Ljubljana, Slovenia article info abstract Article history: It is more than 50 years since the lysosome was discovered. Since then its hydrolytic machinery, including Received 16 August 2011 proteases and other hydrolases, has been fairly well identified and characterized. Among these are the cyste- Received in revised form 3 October 2011 ine cathepsins, members of the family of papain-like cysteine proteases. They have unique reactive-site prop- Accepted 4 October 2011 erties and an uneven tissue-specific expression pattern. In living organisms their activity is a delicate balance Available online 12 October 2011 of expression, targeting, zymogen activation, inhibition by protein inhibitors and degradation. The specificity of their substrate binding sites, small-molecule inhibitor repertoire and crystal structures are providing new Keywords: fi Cysteine cathepsin tools for research and development. Their unique reactive-site properties have made it possible to con ne the Protein inhibitor targets simply by the use of appropriate reactive groups. The epoxysuccinyls still dominate the field, but now Cystatin nitriles seem to be the most appropriate “warhead”.
    [Show full text]
  • Kinetic Properties and Characterization of Purified Proteases from Pacific Whiting
    AN ABSTRACT OF THE THESIS OF JuWen Wu for the degree of Master of Science in Food Science and Technology presented on March 10. 1994 . Title: Kinetic Properties and Characterization of Purified Proteases from Pacific Whiting (Merluccius productus) . Abstract approved: ._ ■^^HaejWg An Kinetic properties of the two proteases, causing textural degradation of Pacific whiting (Merluccius productus) during heating, were compared and characterized with the synthetic substrate, Z-Phe-Arg-NMec. Pacific whiting P-I and P-II showed the highest specificity on Z-Phe-Arg-NMec, specific substrate for cathepsin L. The Km of 1 preactivated P-I and P-II were 62.98 and 76.02 (^M), and kcat, 2.38 and 1.34 (s" ) against Z-Phe-Arg-NMec at pH 7.0 and 30°C, respectively. Optimum pH stability for preactivated P-I and P-II is between 4.5 and 5.5. Both enzymes showed similar pH- induced preactivation profiles at 30oC. The maximal activity for both enzymes was obtained by preactivating the enzyme at a range of pH 5.5 to 7.5. The highest activation rate for both enzymes was determined at pH 7.5. At pH 5.5, the rate to reach the maximal activity was the slowest, but the activity was stable up to 1 hr. P-I and P-II shared similar temperature profiles at pH 5.5 and pH 7.0 studied. Optimum temperatures at pH 5.5 and 7.0 for both proteases on the same substrate were 550C. Significant thermal inactivation for both enzymes was shown at 750C.
    [Show full text]
  • Characterization of the Cathepsin-Like Cysteine Proteinases of Schistosoma Mansoni JOHN P
    INFECTION AND IMMUNITY, Apr. 1996, p. 1328–1334 Vol. 64, No. 4 0019-9567/96/$04.0010 Copyright q 1996, American Society for Microbiology Characterization of the Cathepsin-Like Cysteine Proteinases of Schistosoma mansoni JOHN P. DALTON,1,2 KAREN A. CLOUGH,1 MALCOLM K. JONES,3 1 AND PAUL J. BRINDLEY * Molecular Parasitology Unit, Queensland Institute of Medical Research, and Australian Centre for International & Tropical Health & Nutrition, Post Office, Royal Brisbane Hospital, Queensland 4029,1 and Centre for Microscopy and Microanalysis, University of Queensland, St. Lucia, Queensland 4072,3 Australia, and School of Biological Sciences, Dublin City University, Dublin 9, Republic of Ireland2 Downloaded from Received 5 September 1995/Returned for modification 29 November 1995/Accepted 15 January 1996 Adult Schistosoma mansoni parasites synthesize and secrete both cathepsin L and cathepsin B cysteine proteinases. These cysteine proteinase activities, believed to be involved in hemoglobin digestion by adult schistosomes, were characterized by using specific fluorogenic peptide substrates and zymography. Both cathepsin L- and B-like activities with pH optima of 5.2 and 6.2, respectively, predominated in soluble extracts of worms, and both these activities were secreted by adult worms into the culture medium. The specific activity of cathepsin L was about double that of cathepsin B when each was assayed at its pH optimum, and moreover, the specific activities of cathepsins L and B in extracts of female schistosomes were 50 to 100% higher than in http://iai.asm.org/ extracts of male schistosomes. Analysis of the primary structure of two cloned S. mansoni cathepsins L, here termed cathepsin L1 and cathepsin L2, revealed that they are only 44% similar and that cathepsin L2 showed more identity (52%) with human cathepsin L than with schistosome cathepsin L1.
    [Show full text]